Ramatroban is under clinical development by KARE Biosciences and currently in Phase III for Coronavirus Disease 2019 (COVID-19). According to GlobalData, Phase III drugs for Coronavirus Disease 2019 (COVID-19) have a 13% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how Ramatroban’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

Related Company Profiles

View all

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Ramatroban overview

Ramatroban is under development for the treatment of coronavirus disease 2019 (COVID-19), COVID-19 pneumonia, contact dermatitis, acute myocardial infarction, sepsis, influenza-associated pneumonia, silicosis, pulmonary arterial hypertension, sickle cell disease, dengue fever, adult respiratory syncytial virus (RSV), lupus nephritis and idiopathic pulmonary fibrosis. It acts by targeting thromboxane A2/TP and prostaglandin D2/DP2 receptors. It is administered through oral route.

KARE Biosciences overview

KARE Biosciences is an biotechnology company which focuses on ramatroban for the treatment of acute COVID-19 and long COVID. KARE Biosciences is headquartered in Orange, California, the US.

For a complete picture of Ramatroban’s drug-specific PTSR and LoA scores, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.